4Q Pharma Results Preview: J&J, Novartis, Bristol, Celgene, Biogen
Scrip offers some key points to watch for as Johnson & Johnson and Novartis kick off the big pharma full-year presentations Jan. 24, with Bristol-Myers Squibb, Celgene and Biogen Idec finishing off the first week of earnings season.
You may also be interested in...
Patent Settlement Offers Some Salve For Bristol’s PD-1 Wounds
Bristol-Myers Squibb has taken a beating over setbacks for its Opdivo and its immuno-oncology portfolio, but a settlement reached with Merck over Keytruda’s patent infringement is a momentary victory for the PD-1 pioneer.
Game Changer: Merck's Stealth Keytruda-Chemo Filing Stirs NSCLC Market Dynamics
Merck & Co. has stealthily filed its highly anticipated Keytruda plus chemotherapy combination for first-line treatment of non-small cell lung cancer on the back of Phase II data, months earlier than expected and before the completion of a Phase III study.
Pharma Strategizes On Drug Pricing On Day One Of J.P. Morgan
Drug pricing was a big theme at the industry’s biggest business meeting of the year, and it’s poised to remain one throughout 2017. While drug makers acknowledged issues, they mostly defended their pricing strategies.